Biotechnology

124 articles in this category (Page 2 of 6)

HealthcareBiotechnologyTechnical Analysis

Sarepta Therapeutics (SRPT): Overbought Technicals and Margin Concerns Signal Short-Term Pullback Despite Clinical Data Spike

Despite a 20% surge on promising Phase 1/2 clinical data, SRPT faces immediate pullback risks due to an extreme RSI of 83.42 and severe operational inefficiencies.

Mar 25, 2026SRPT

RegulatoryBiotechnologyFinancial Analysis

ImmunityBio (IBRX) Faces Regulatory Headwinds Amidst FDA Warning: 21-Day Decrease Expected (Confidence: 5/10)

A recent FDA warning letter regarding misleading marketing for ANKTIVA threatens ImmunityBio's momentum despite surging revenue, pointing to further downside risk.

Mar 24, 2026IBRX

HealthcareBiotechnologyClinical Trials

Apogee Therapeutics (APGE): 5-Day Bullish Outlook Driven by Positive Phase 2 APEX Trial Data

Apogee Therapeutics is poised for short-term upside following highly positive 52-week Phase 2 data for zumilokibart and subsequent analyst price target hikes.

Mar 23, 2026APGE

EarningsGuidanceBiotechnology

BioNTech SE (BNTX): Earnings Shock and Lowered Guidance Point to Sideways Consolidation Amid Oversold Technicals

Lowered 2026 revenue guidance and a major management transition clash with a massive cash floor and deeply oversold technicals, signaling near-term consolidation.

Mar 10, 2026BNTX

HealthcareBiotechnologyClinical Trials

Xenon Pharmaceuticals (XENE) 5-Day Outlook: Imminent Phase 3 Catalyst Clashes with Overbought Technicals

An impending Phase 3 data readout for azetukalner presents a massive binary catalyst, though extreme overbought technicals cap near-term upside confidence.

Mar 9, 2026XENE

HealthcareBiotechnologyFinancial Analysis

DAWN Faces Overbought Technicals Amid Stale Catalysts and Massive Margin Gaps: Sideways Outlook

With an RSI of 82.00 and no fresh catalysts, DAWN is expected to trade sideways as massive operational costs offset strong gross margins.

Mar 6, 2026DAWN

HealthcareBiotechnologyRegulatory

ImmunityBio (IBRX): 5-Day Bullish Outlook Driven by EU ANKTIVA Approval Amidst Cash Burn Risks

ImmunityBio's recent EU marketing authorization for ANKTIVA provides a strong short-term bullish catalyst, though extreme negative margins cap long-term confidence.

Mar 4, 2026IBRX

EarningsBiotechnologyMarket Analysis

ImmunityBio (IBRX) Faces Post-Earnings Selloff Despite Revenue Surge: 5-Day Decrease Expected (Confidence: 5/10)

Despite a 700% revenue surge, ImmunityBio's massive net losses and negative free cash flow trigger a short-term bearish outlook.

Feb 25, 2026IBRX

EarningsTechnical AnalysisBiotechnology

ACLX 5-Day Outlook: Extreme Overbought Conditions and Earnings Risk Threaten Recent 78% Surge

Despite 100% bullish news sentiment, Arcellx faces severe pullback risks as its RSI hits 82.85 and shares trade above the average analyst price target ahead of its February 26 earnings.

Feb 23, 2026ACLX

BiotechnologyHealthcare

EU Approval Fuels Rally, But Profits Remain Distant: A 21-Day Outlook for ImmunityBio

Quantitative analysis of ImmunityBio (IBRX) following a strict 12-step methodology, focusing on the impact of the EU approval for Anktiva and upcoming earnings within a 21-day horizon.

Feb 18, 2026IBRX

BiotechnologyHealthcare

Stale News and Neutral Sentiment Point to Sideways Trading Ahead of Earnings

Quantitative analysis of Disc Medicine (IRON) based on provided financial data and structured news, following strict methodological rules.

Feb 16, 2026IRON

BiotechnologyHealthcareHigh Beta

Oversold IRON Awaits Earnings Catalyst; Sideways Drift Likely Until Then

Quantitative analysis of Disc Medicine (IRON) integrating recent neutral news, oversold technicals, high volatility profile, and a lack of immediate, specific price catalysts ahead of earnings.

Feb 13, 2026IRON

Stock Weather AIBiotechnologyCatalyst-Driven

ImmunityBio – 2026-02-09 - Increase Confidence 6/10

Strong technical momentum and a key insider debt conversion ease near-term dilution fears, supporting a potential price increase.

Feb 9, 2026IBRX

AI NewsBiotechnologyProtein Synthesis

GPT-5 Lowers Cell-Free Protein Synthesis Costs by 40%

An autonomous lab combining OpenAI’s GPT-5 with Ginkgo Bioworks’ cloud automation cut cell-free protein synthesis costs by 40% through closed-loop experimentation.

Feb 5, 2026

Stock Weather AIBiotechnologySpeculative Stocks

Regencell Bioscience – 2026-02-02 - Decrease Confidence 8/10

Zero revenue and extreme speculative run-up signal a high probability of a sharp correction in the coming days.

Feb 2, 2026RGC

Stock Weather AIBiotechnologyGrowth Stocks

Twist Bioscience Corporation – 2026-02-02 - Increase Confidence 6/10

Strong institutional conviction and a beat on revenue estimates provide a near-term catalyst, but persistent losses and high volatility temper the outlook.

Feb 2, 2026TWST

Stock Weather AIBiotechnologyM&A Speculation

Revolution Medicines – 2026-01-26 - increase Confidence 7/10

Negative free cash flow contrasts with Merck's terminated $32B acquisition talks and upcoming 2026 clinical catalysts, signaling near-term upside potential.

Jan 26, 2026RVMD

Stock Weather AIBiotechnologyClinical Catalysts

ImmunityBio – 2026-01-23 - increase Confidence 8/10

Surging ANKTIVA sales and FDA clearance path signal strong near-term upside despite negative margins.

Jan 23, 2026IBRX

Stock Weather AIBiotechnologyEarnings Catalyst

Legend Biotech – 2026-01-21 - Increase Confidence 7/10

Negative free cash flow persists, but 2026 profitability guidance and CARVYKTI's label update act as catalysts for near-term upside.

Jan 21, 2026LEGN

Stock Weather AIBiotechnologyClinical Trials

Moderna – 2026-01-21 - Increase Confidence 8/10

Negative free cash flow and high leverage offset by strong clinical catalysts and upward revenue guidance, driving near-term upside.

Jan 21, 2026MRNA

Stock Weather AIBiotechnologyClinical Catalysts

ImmunityBio – 2026-01-20 - Increase Confidence 8/10

Negative free cash flow contrasts with explosive 700% revenue growth and FDA progress, triggering strong near-term upside potential.

Jan 20, 2026IBRX

Stock Weather AIBiotechnologyGrowth Stocks

ImmunityBio – 2026-01-19 - Increase Confidence 8/10

Surging revenue and Saudi FDA approval catalyze momentum; stock poised for near-term upside despite structural losses.

Jan 19, 2026IBRX

Stock Weather AIBiotechnologyGrowth Stocks

ImmunityBio – 2026-01-16 - Increase Confidence 8/10

700% revenue growth and Saudi FDA approval act as catalysts; cash runway supports execution, pointing to near-term upside.

Jan 16, 2026IBRX

Stock Weather AIBiotechnologyClinical Trials

Erasca, Inc. – 2026-01-15 - increase Confidence 8/10

Negative free cash flow is offset by $362.4M cash runway and recent positive clinical data for ERAS-0015, triggering analyst upgrades and technical bullishness, pointing to near-term price increase.

Jan 15, 2026ERAS